Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19

Award Number: R01AI178605
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/13/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19 - We propose in this application a novel therapeutic approach for the eradication of CoV-2. We developed a new strategy, which consists of hijacking the viral replication machinery to trigger the death of CoV-2-infected cells, while preserving uninfected cells. We propose to administer intranasally human ACE2 transgenic mice a “tailored” RNA encoding the diphtheria toxin fragment A (DTA) called {CoV-2 Hijack DTA} that is only recognized and transcribed by the CoV-2 polymerase (Pol/RdRp) present in infected cells, triggering DTA expression and rapid death of infected cells. Since DTA cannot cross the cellular membrane, it cannot kill uninfected cells. Because RNA can be easily broken down in the body, it needs to be transported within a protective carrier. Noninvasive aerosol inhalation is a well-established method of drug delivery to the respiratory tract and represents an ideal route for nucleic-acid-based therapeutics as demonstrated in various clinical trials. We propose to design degradable polymer-lipid nanoparticles (LNPs) that can deliver RNAs by nebulization (inhalation) to the respiratory tract. We propose to synthesize hyperbranched poly-beta amino esters (hPBAEs) to enable nanoformulation by nebulizer of stable and concentrated polyplexes suitable for inhalation. This strategy should achieve uniform distribution of RNAs throughout lungs resulting in high levels of proteins of interest 24h post-inhalation of hPBAE polyplexes without local or systemic toxicity due to rapid degradation of hPBAE vectors. The safety and antiviral efficacy of nebulized {CoV-2 Hijack DTA} RNA LNPs stably protected by degradable hPBAEs will be analyzed in CoV-2 variant-infected mice. Our in vivo imaging IVIS Lumina S5 system permits a daily bioluminescence (NanoLuc-CoV-2) or fluorescence (mNeonGreen CoV-2) quantification of the {CoV-2 Hijack DTA} RNA LNPs-mediated killing of infected lungs in live mice. Viral and host events required for the beneficial therapeutic effect of {CoV-2 Hijack DTA} RNA LNPs will be investigated including caspase pathway activation, membrane permeability and chromosomal degradation of infected lung cells as well as the prevention of the development of interstitial pneumonia and cytokine cascade. In summary, this application proposes to demonstrate the safety and efficacy of this novel therapeutic approach that consists of hijacking the enzymatic viral replication machinery to trigger the specific killing of CoV-2-infected cells, but not of uninfected cells. Importantly, {CoV-2 Hijack DTA} RNA LNPs will be administered at different time points of the infection in order to compare the preventive and therapeutic efficacy of our novel approach.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $749,787 )
2026	2026	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	3	5/13/2026	NON-COMPETING CONTINUATION	$749,787
														Subtotal = $749,787

Issue Date FY: 2025 ( Subtotal = $749,787 )
2025	2025	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	001	2	8/19/2025	NON-COMPETING CONTINUATION	$0
2025	2025	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	2	6/25/2025	NON-COMPETING CONTINUATION	$749,787
														Subtotal = $749,787

Issue Date FY: 2024 ( Subtotal = $775,538 )
2024	2024	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	000	1	6/13/2024	NEW	$697,983
2024	2024	SCRIPPS RESEARCH INSTITUTE	10550 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Allergy and Infectious Diseases Research	001	1	9/3/2024	NEW	$77,555
														Subtotal = $775,538

Grand Total All Awards = $2,275,112

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19

Award Number: R01AI178605

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/13/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer